Loading...
Market
PTC518 FDA Approval for Huntington's by End of 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements and press releases
Story
PTC Therapeutics Secures $2.9B Deal with Novartis for Huntington's Drug, $1B Upfront
Dec 2, 2024, 01:09 PM
PTC Therapeutics Inc. has entered into a significant licensing agreement with Novartis AG, focusing on the development of PTC518, an experimental drug for Huntington's disease. The deal, which could be worth up to $2.9 billion, includes an upfront payment of $1 billion to PTC Therapeutics. Under the terms, Novartis will share U.S. profits and losses with PTC Therapeutics on a 40/60 basis, with PTC receiving 40%. This collaboration marks Novartis's renewed interest in Huntington's disease treatments. The agreement also involves global licensing and collaboration for the drug's development, with Novartis taking the lead in further development efforts.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Yes • 50%
No • 50%
Breakthrough Therapy Designation • 25%
Orphan Drug Designation • 25%
Priority Review • 25%
No additional designations • 25%
Full Approval • 25%
Accelerated Approval • 25%
Conditional Approval • 25%
Rejection • 25%
